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Available online xxxxPrimary headaches may be accompanied by increased intracranial blood ﬂow induced by the release of the po-
tent vasodilator calcitonin gene-related peptide (CGRP) from activatedmeningeal afferents. We aimed to record
meningeal and medullary blood ﬂow simultaneously and to localize the sites of CGRP release in rodent prepara-
tions in vivo and ex vivo.
Blood ﬂow in the exposed rat parietal dura mater and the medulla oblongata was recorded by laser Doppler
ﬂowmetry, while the dura was stimulated by topical application of 60 mM potassium chloride (KCl). Samples
of jugular venous plasma and cerebrospinal ﬂuid (CSF) collected from the cisterna magna were analysed for
CGRP concentrations using an enzyme immunoassay. In a hemisected rat skull preparation lined with dura
mater the CGRP releasing effect of KCl superfusion was examined.
Superfusion of the dura mater with KCl decreased meningeal blood ﬂow unless alpha-adrenoceptors were
blocked by phentolamine, whereas the medullary blood ﬂow was increased. The same treatment caused in-
creased CGRP concentrations in jugular plasma and CSF and induced signiﬁcant CGRP release in the hemisected
rat skull preparation. Anaesthesia of the trigeminal ganglion by injection of lidocaine reduced increases in med-
ullary blood ﬂow and CGRP concentration in the CSF upon meningeal KCl application.
CGRP release evoked by depolarisation ofmeningeal afferents is accompanied by increased blood ﬂow in theme-
dulla oblongata but not the duramater. This discrepancy can be explained by the smoothmuscle depolarising ef-
fect of KCl and the activation of sympathetic vasoconstrictor mechanisms. The medullary blood ﬂow response is
most likely mediated by CGRP released from activated central terminals of trigeminal afferents. Increased blood
supply of the medulla oblongata and CGRP release into the CSF may also occur in headaches accompanying vig-
orous activation of meningeal afferents.
© 2017 Elsevier Ltd. All rights reserved.Keywords:
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Headache1. Introduction
The cranial dura mater and cerebral arteries are innervated by un-
myelinated and thinly myelinated afferent nerve ﬁbers arising from
the trigeminal ganglion (Andres et al., 1987; Steiger and Meakin,
1984). An exclusively nociceptive function is attributed to these affer-
ents, based on classical intraoperative studies showing that stimulation
of meningeal structures evokes no other sensation than headaches
(Feindel et al., 1960; Ray and Wolff, 1940). A considerable proportion
of meningeal afferents contains neuropeptides like calcitonin gene-re-
lated peptide (CGRP) (Keller and Marfurt, 1991; Messlinger et al.,
1995; O'Connor and van der Kooy, 1988) and CGRP release is an
established method to quantify meningeal afferent activation in vitroPathophysiology, University of
, Germany.
).
ulation of rat cranial duramat
2017), http://dx.doi.org/10.1and in vivo (Bellamy et al., 2006; Ebersberger et al., 1999; Goadsby et
al., 1988). CGRP is a potent vasodilator of intracranial arteries inducing
increases in meningeal blood ﬂow (Escott et al., 1995; Jansen-Olesen
et al., 1996;Messlinger et al., 1995). Thus recordings ofmeningeal vaso-
dilatation and blood ﬂow have been used to examine the effects of
chemical mediators presumably involved in meningeal nociception
(Akerman et al., 2002; Dux et al., 2002; Escott et al., 1995) and to test
substances designed for headache therapy (Messlinger et al., 1997;
Petersen et al., 2005; Tröltzsch et al., 2007). CGRP can also be released
from the trigeminal ganglion (Eberhardt et al., 2009) and from central
terminals of trigeminal afferents within the spinal trigeminal nucleus
(Amrutkar et al., 2011; Jansen-Olesen et al., 2014; Kageneck et al.,
2014; Offenhauser et al., 2005),where it actsmost likely as pro-nocicep-
tive mediator (Meng et al., 2009; Storer et al., 2004).
Although CGRP has been attributed a key role in primary headaches
for many years (Arulmani et al., 2004a; Edvinsson and Goadsby, 1994;
Goadsby and Edvinsson, 1994; Lassen et al., 2002), its nociceptiveer with potassium chloride causes CGRP release into the cerebrospinal
016/j.npep.2017.02.080
Fig. 1. Experimental setup (A) and changes in meningeal and medullary blood ﬂow
(normalized to baseline) during topical application of potassium chloride (KCl 60 mM)
onto the dura mater (B, C). A: Laser Doppler L-type needle probes were positioned upon
arterial vessels in the exposed dura mater and the medulla oblongata. Collection of
cerebrospinal ﬂuid (CSF) from the surface of the medulla and of jugular venous blood
was combined with ﬂow measurements and with injection of lidocaine into the
trigeminal ganglion (TG) in some series of experiments. B: Response of dural blood
vessels to KCl before and after phentolamine hydrochloride (100 μM) measured at
intervals of 2 min; # different to baseline (ANOVA), * different to the effect of KCl prior
to blocking alpha-adrenoceptors (t-test; n = 10). C: Effect of trigeminal ganglion
anaesthesia on medullary blood ﬂow induced by KCl (60 mM); # different to baseline
(ANOVA),* different to the effect of KCl prior to ganglion anaesthesia (t-test; n = 10).
2 M. Dux et al. / Neuropeptides xxx (2017) xxx–xxxfunction remains elusive. Increases in CGRP plasma levels have been
found in acute phases of migraine and cluster headache (Bellamy et
al., 2006; Goadsby et al., 1988, 1990) and also interictally in chronic mi-
graine (Cernuda-Morollón et al., 2013). Inhibition of CGRP receptors is
clearly therapeutic in migraine (Ho et al., 2008; Olesen et al., 2004)
and inactivation of CGRP or CGRP receptors by four newly developed
humanized monoclonal antibodies is promising in reducing the fre-
quency of headache attacks in chronic and frequent migraine based on
a variety of clinical phase-3 studies (Bigal et al., 2015; Dux and
Messlinger, 2015; Giamberardino et al., 2016; Schuster and Rapoport,
2016).
The lack of understanding the role of CGRP in migraine pain may be
partly due to our ignorance of its precise sites of release and action.
While there is no doubt that CGRP is releasedwhenmeningeal afferents
are massively activated, it is unclear whether the bulk of CGRP found in
plasma samples is released at peripheral or central sites in animal ex-
periments (Goadsby et al., 1988) as well as in patients during headache
attacks (Bellamy et al., 2006; Goadsby et al., 1990). CGRP released from
central afferent terminals or from afferents innervating pial blood ves-
sels can be expected to accumulate in the cerebrospinal ﬂuid (CFS) rath-
er than in the venous compartment due to the blood-brain barrier.
Finally, blood ﬂow increase should also occur in the medullary dorsal
area, when central trigeminal afferents are activated. Release of CGRP
during nociceptive processing may thereby support the blood supply
of central structures for an increased metabolism. Using video imaging,
our group has recently shown that local electrical stimulation of the rat
cranial dura mater causes vasodilatation of pial arteries of the dorsal
medulla (Will et al., 2016).
The preparation described here extends our established models of
meningeal nociception which employed CGRP release from meningeal
afferents in the hemisected rodent skull preparation (Ebersberger et
al., 1999; Fischer and Messlinger, 2007; Gupta et al., 2010), trigeminal
ganglion (Eberhardt et al., 2008) and brainstem (Amrutkar et al.,
2011; Kageneck et al., 2014) and meningeal blood ﬂow recordings in
the exposed cranial dura mater in rats (Dux and Messlinger, 2001;
Dux et al., 2003; Kurosawa et al., 1995). The aim of the present study
was to measure CGRP concentrations in samples of jugular plasma and
CSF of the cisterna cerebello-medullaris (cisterna magna) together
with changes in medullary blood ﬂow provoked by chemical depolari-
zation of meningeal afferents as a rat model of meningeal nociception
(Fig. 1A). We hypothesized that massive activation of meningeal affer-
ents, as it is assumed to occur in severe headaches, causes release of
CGRP into plasma and CSF and is accompanied by an increase in blood
ﬂow not only in the cranial dura mater but also in pial blood vessels of
the medulla oblongata.
2. Methods
2.1. Experimental animals and surgery
All experimental procedureswere carried out in accordancewith the
ethical issues of the International Association for the Study of Pain and
in compliance with the guidelines for the welfare of experimental ani-
mals of the Federal Republic of Germany and the European Union
(Council Directive 2010/63/EU). The experimental protocols were
reviewed by an ethics committee and approved by the local District
Government. Efforts were made to keep the number of animals as low
as possible. Adult male Wistar rats weighing 300–400 g (10–14 weeks
old) were used. The animals were anaesthetized with 5% isoﬂurane
(Forene, Abbott, Wiesbaden, Germany) inhaled in a closed box, contin-
ued by application of 2% isoﬂurane through a tightmask. Inmost exper-
iments for plasma CGRP measurements (see below) animals were
initially anaesthetized with intraperitoneal (i.p.) application of 120–
150 mg/kg thiopentone (Trapanal®, Altana, Konstanz, Germany). Fem-
oral artery and vein were cannulated for recording of blood pressure
and intravenous (i.v.) infusion of substances. In animals designated forPlease cite this article as: Dux, M., et al., Stimulation of rat cranial duramat
ﬂuid and increases medul..., Neuropeptides (2017), http://dx.doi.org/10.1venous blood sampling, a plastic catheter was introduced in cranial di-
rection into the jugular vein of the side ipsilateral to the trepanation
(see below) and ﬂushed with saline containing 10 U/ml heparin
(Ratiopharm, Ulm, Germany). The opening of the catheter was placed
close to the bifurcation of the jugular vein. The animals were
tracheotomized and artiﬁcially ventilated with a mixture of oxygen-er with potassium chloride causes CGRP release into the cerebrospinal
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CGRP measurements anaesthesia was maintained by small doses of
thiopentone (25 mg/kg i.p. or 10 mg/kg i.v.) when required. There
was no obvious difference between the measurements in plasma ob-
tained from animals anaesthetized with either of these procedures.
Depth of anaesthesia was routinely assessed and held at a level in
which noxious stimuli (pinching of earlobes) failed to elicit motor re-
ﬂexes or changes in systemic arterial pressure. The body temperature
of the animals was recorded with a thermoprobe inserted into the rec-
tum and was kept at 37–37.5 °C with a feedback-controlled heating
pad (TKM 0902, Föhr Medical Instruments, Seeheim, Germany). Sys-
temic blood pressure was recordedwith a pressure transducer connect-
ed to the catheter inserted into the right femoral artery. The expiratory
CO2 was continuously monitored (Artema MM 200, Karl Heyer, Bad
Ems, Germany) and maintained at 3–3.5%.
The head of the animal was ﬁxed in a stereotaxic frame and the skin
overlying the skull and the neck region was opened. The neck muscles
were divided along themidline and themedulla oblongatawas exposed
by cutting the atlanto-occipital ligament and the underlying duramater
(Fig. 1A). For dural blood ﬂow recording a cranial window was drilled
into the parietal bone, exposing the branches of the middle meningeal
artery (Kurosawa et al., 1995). To avoid thermal lesions, a saline-cooled
drill was used. For trigeminal ganglion anaesthesia a thin silicon tube
connected to a 27-gauge needle was ﬁlled with fractions of 40 μl of 2%
lidocaine hydrochloride (Xylocain, AstraZeneca, Wedel, Germany) and
40 μl of 0.1% methylene blue (Sigma, Taufkirchen, Germany) separated
by an air bubble of 10 μl. The needle was introduced through the
infraorbital canal into the ipsilateral trigeminal ganglion (Fig. 1A). At
the end of the experiments, the animals were killed with an overdose
of thiopentone (250 mg/kg i.v.).
2.2. Measurement of medullary and dural blood ﬂow and systemic arterial
pressure
The exposed dura mater in the cranial window was covered with
40 μl of synthetic interstitial ﬂuid (SIF) containing (in mM): 107.8
NaCl, 26.2 NaHCO3, 9.64 Na-gluconate, 7.6 sucrose, 5.55 glucose, 3.5
KCl, 1.67 NaH2PO4, 1.53 CaCl2 and 0.69 MgSO4, buffered to pH 7.4 with
carbogen gas (95% O2, 5% CO2). For stimulation with KCl, the SIF was re-
placed by SIF containing 60 mM KCl. Solutions were removed after
10 min and the dura mater was washed repeatedly with SIF to allow
the bloodﬂow to return to the basal level. In some experiments thenon-
selective alpha-adrenergic antagonist phentolamine hydrochloride at
100 μM (Sigma, Taufkirchen, Germany) was applied to the dura mater
for 5 min prior to stimulation with 60 mM KCl.
Medullary and dural blood ﬂow was recorded with needle L-type
probes of a laser Doppler ﬂowmeter (DRT4, Moor Instruments, Axmin-
ster, UK) positioned over the arterial blood vessels of the exposed dorsal
surface of themedulla oblongata and branches of themiddlemeningeal
artery supplying the dura mater (Fig. 1A). Blood ﬂowwas recorded at a
sampling rate of 10 Hz and expressed in arbitrary units (AU). Medullary
and meningeal blood ﬂow and systemic blood pressure of the animals
were recorded simultaneously. Data were stored and processed with
the MoorSoft program for Windows. The basal blood ﬂow (baseline)
was the mean ﬂow value measured during a 3 minute period prior to
the stimulation of the dura mater. Percentage changes in meningeal
and medullary blood ﬂow in response to KCl application were deter-
mined as mean ﬂow values within the 10 min application period calcu-
lated separately at two-minute intervals relative to the basal ﬂow. The
possible contribution of sympathetic mechanisms to the KCl-induced
vascular response was determined by comparing the changes in blood
ﬂow in response to KCl before and after topical application of the
alpha-adrenergic antagonist phentolamine hydrochloride (100 μM,
Sigma, Taufkirchen, Germany). In parallel, themean arterial blood pres-
sure was registered during the whole stimulation period and compared
to baseline.Please cite this article as: Dux, M., et al., Stimulation of rat cranial duramat
ﬂuid and increases medul..., Neuropeptides (2017), http://dx.doi.org/10.1After deﬁning the effect of KCl on meningeal and medullary blood
ﬂow the trigeminal ganglionwas anaesthetised by slowly injecting lido-
caine through the catheter inserted into the ganglion. Twominutes later
60 mM KCl was applied to the dura mater for 10 min while the medul-
lary blood ﬂow was recorded. The effect of trigeminal ganglion anaes-
thesia on the KCl-induced medullary blood ﬂow was determined by
comparing blood ﬂow measured before and after lidocain injection
into the ganglion. At the end of the experiment the correct position of
the injection needle was controlled by injection of methylene blue and
subsequent dissection of the trigeminal ganglion. Experiments in
which the ganglion showed no blue staining were discarded.
2.3. Measurement of CGRP concentration in plasma and cerebrospinal ﬂuid
Venous blood samples of 300 μl were taken through the jugular cath-
eter at intervals of 15 min with a 1 ml syringe containing 10 μl of 0.5 M
EDTA (Sigma, Taufkirchen, Germany) to prevent blood coagulation.
Each blood sample was immediately transferred to Eppendorf cups
and dilutedwith 60 μl enzyme-linked immunoassay (EIA) buffer (Bertin
Pharma/SPIbio, Montigny le Bretonneux, France) containing peptidase
inhibitors. The samples were centrifuged at 2500 rpm for 2 min, then
the plasma supernatant was taken off with a pipette and stored
at−20 °C for later analysis. Care was taken not to cause hemolysis dur-
ing each step of this procedure.
The CSF covering the exposed dorsal surface of the medulla
oblongata was collected with a micropipette without touching the tis-
sue. First the impact of the head surgery on the CGRP concentration in
the CSF was studied. A ﬁrst sample of 25 μl CSF was collected immedi-
ately after opening the cisterna magna and a second 15 min later.
After trepanation of the skull, three to six other CSF samples of 25 μl
were taken at intervals of 15 min. In the main experiments starting
30 min after completing the surgery when the postpreparatory values
of CGRP concentration in the CSF had reached a stable baseline level,
the effects of KCl stimulation (60 mM) were determined by comparing
the CGRP concentrations of CSF samples taken 10min before and imme-
diately after stimulation of the dura mater. All samples were immedi-
ately transferred to Eppendorf cups and diluted with EIA buffer at a
volume of 4 times the volume of CSF, then they were stored at−20 °C
for later analysis.
The CGRP content of the samples was measured by EIA (Bertin
Pharma/SPIbio, Montigny le Bretonneux, France). The absorbance of
the reaction product representing the CGRP content of the sample was
determined photometrically, using a microplate reader (Opsys MR,
Dynex Technologies, Denkendorf, Germany). The lower limit of detec-
tion is 5 pg/ml CGRP as communicated by themanufacturer. The plasma
CGRP concentration was calculated in pg/ml. Changes induced in CGRP
release by KCl were expressed as percentage changes relative to the
basal release.
2.4. Ex vivo measurements of meningeal CGRP release
An ex vivo rat dura mater preparation was used to assess the release
of CGRP from meningeal afferents. Rats were decapitated after lethal
CO2 inhalation. The skull was divided into halves along the midline
after the removal of the skin and themuscles. The cerebral hemispheres
were removed, skull halves were washed at room temperature for
30 min in SIF, then placed in a humid chamber and the cranial fossae
were ﬁlled with 400 μl SIF. Samples of the superfusate were collected
with a micropipette at periods of 5 min for CGRP measurement. Two
control samples were taken in order to determine basal CGRP release
then the durawas stimulatedwith 60mMKCl. 100 μl of samples diluted
with 25 μl EIA buffer were placed into Eppendorf cups and immediately
frozen at−20 °C for subsequent analysis with EIA as described above.
The CGRP concentrations of the superfusates were measured in pg/ml
and expressed as percentage changes relative to the basal release.er with potassium chloride causes CGRP release into the cerebrospinal
016/j.npep.2017.02.080
4 M. Dux et al. / Neuropeptides xxx (2017) xxx–xxx2.5. CGRP- and tyrosine hydroxylase-immunhistochemistry of dura and pia
mater
After the measurements of medullary and meningeal blood ﬂow
the animals were injected with an overdose of thiopentone. Immedi-
ately after cessation of spontaneous breathing but ongoing heart
beat they were thoracotomized and perfused through the ventricle
with 200 ml saline followed by 200 ml of 4% paraformaldehyde in
phosphate buffer (pH 7.4). The brain including dura mater and me-
dulla was dissected and postﬁxed for 24 h. Then the cranial dura
mater and the medullary pia mater were carefully removed and
processed as a whole mount for staining with the indirect immuno-
ﬂuorescence technique using a rabbit polyclonal antiserum raised
against CGRP (1:100, Dianova, Hamburg, Germany) and (for the
dura mater) a sheep polyclonal antiserum raised against tyrosine hy-
droxylase (1:2000, Novus Biologicals, Littleton, CO, USA). Donkey
anti-rabbit or anti-sheep IgG (1:1000) labeled with Alexa 488 or
Alexa 555 (Molecular Probes, Eugene, OR, USA) were used as second-
ary antibodies. Tissues were examined with a ﬂuorescence micro-
scope (Leica MZ FLIII, Leica Microsystems, Bensheim, Germany)
equipped with a Leica DFC 320 digital camera system. Confocal im-
ages were taken with appropriate ﬁlter and pinhole settings using a
20× dry objective lens and sequential scanning. Single planes or
stacks of images were merged into a 515 × 512 pixel RGB tiff-ﬁle
using confocal software ZEN 2010. The ﬁnal layout was made with
CorelDraw (Corel, Dublin, Ireland).2.6. Statistics
Sample sizeswere determined using power calculations on the basis
of previous experiments, from which the variance of changes in blood
ﬂow and CGRP release induced by meningeal stimulation were
known. Pre- and poststimulation values were compared using the
paired Student's t-test (for n ≥ 10) or the Wilcoxon test (for n b 10)
and presented as means ± SEM. ANOVA with repeated measurements
and Fisher's least signiﬁcant difference (LSD) test were used to analyze
the consecutivemeasurements of CGRP levels at intervals of 15min and
the ﬂow values at two-minute intervals. P b 0.05 was considered statis-
tically signiﬁcant.3. Results
3.1. Stimulation-induced changes in meningeal blood ﬂow
The application of depolarizing KCl (60 mM) onto the dura mater
in 10 experiments decreased the meningeal blood ﬂow within 2 min
by 15.6 ± 6.1%, which was signiﬁcant up to the 6th min (repeated
measures ANOVA and LSD-test, p b 0.001–0.05) before it slowly re-
covered approximating the baseline towards the end of the 10-min
application period (Fig. 1B). Five minutes after pretreatment of the
dura mater with the alpha-adrenoceptor antagonist phentolamine,
KCl application was followed by a tendency of increased meningeal
blood ﬂow, which was not signiﬁcant within the 10 min application
period compared to baseline (repeated measures ANOVA). The dif-
ference between the normalized ﬂow values of the corresponding
time intervals before and after phentolamine was signiﬁcant up to
the 6th min (two-way repeated measures ANOVA and LSD test,
p b 0.001–0.05) (Fig. 1B).
Injection of lidocaine into the ipsilateral trigeminal ganglion in
10 experiments did not cause signiﬁcant changes in basal meninge-
al blood ﬂow (t-test). The subsequent application of KCl was not
followed by a signiﬁcant change in ﬂow increase compared to the
effect of KCl before ganglion anaesthesia (repeated measures
ANOVA).Please cite this article as: Dux, M., et al., Stimulation of rat cranial duramat
ﬂuid and increases medul..., Neuropeptides (2017), http://dx.doi.org/10.13.2. Stimulation-induced changes in medullary blood ﬂow and arterial
blood pressure
Application of KCl to the dura mater in 10 experiments induced a
small but consistent increase in medullary blood ﬂow from the 2nd
two-min interval (ANOVA and LSD test, p ≤ 0.01). Themaximal increase
by 3.6 ± 0.5% occurred towards the end of the 10-min application peri-
od (Fig. 1C).
Injection of lidocaine into the trigeminal ganglion in 10 experiments
did not signiﬁcantly change the basal medullary ﬂow (t-test). However,
after lidocaine injection, meningeal KCl application did no longer cause
signiﬁcant changes in medullary blood ﬂow (repeated measures
ANOVA). The difference between the normalized ﬂow values of the cor-
responding time intervals before and after lidocaine injection was sig-
niﬁcant throughout the 10-min period (two-way repeated measures
ANOVA and LSD test, p b 0.001) (Fig. 1C).
Systemic arterial blood pressure of the animals was 87.6± 1mmHg
throughout the experiments. Neither meningeal application of KCl or
phentolamine hydrochloride nor injection of lidocaine into the trigem-
inal ganglion caused signiﬁcant changes in arterial blood pressure.
3.3. Stimulation-induced changes in CGRP levels in CSF
CSF taken immediately after opening the cisterna magna contained
245 ± 25 pg/ml CGRP, a second sample 15 min later 133 ± 20 pg/ml.
Around 15min after craniotomy the CGRP concentrations in the CSF fur-
ther decreased to 108 ± 12 pg/ml. The CGRP concentration of four fol-
lowing CSF samples collected at intervals of 15 min still tended to
decrease but values were not signiﬁcantly different compared to the
previous measurement (n = 8–24, repeated measures ANOVA and
LSD post-hoc test, Fig. 2A). Thus, for the main experiments we started
dural stimulation and CSF sampling only 30 min after completing the
trepanation.
In samples taken after KCl application onto the dura mater the CGRP
concentrationwas increased from 84.3± 4.9 pg/ml to 94.9± 6.1 pg/ml,
i.e. by 14.5 ± 5.7% over baseline (n= 18, t-test, p= 0.043, Fig. 2B). In-
jection of lidocaine into the trigeminal ganglion had no effect on CGRP
concentrations in the CSF but abolished the CGRP releasing effect of
meningeal KCl application (Fig. 2C). After ganglion anaesthesia in 8 ex-
periments the CGRP concentration in the CSF following KCl application
to the dura mater remained nearly at baseline (91 ± 9.1% of baseline)
with no signiﬁcant change (Wilcoxon, p= 0.24).
3.4. Stimulation-induced changes in plasma levels of CGRP
Basal levels of CGRP in the jugular venous plasma taken 10min prior
to stimulation of the duramaterwith 60mMKClwere 15.0±2.8 pg/ml.
In the sample taken after stimulation the CGRP concentration in the jug-
ular plasma was increased to 21.8 ± 2.8 pg/ml (148% of the basal con-
centration; Wilcoxon, n= 8, p= 0.017) (Fig. 2D).
3.5. CGRP concentrations in the hemisected cranial preparation
In the ex vivo hemisected rat skull preparation with adhering dura
mater the basal release of CGRP measured in the incubation ﬂuid was
15.6 ± 4.7 pg/ml (n= 8). KCl application at 60 mM concentration in-
creased the CGRP concentration to 76.7±14.9 pg/ml (492% of the base-
line; Wilcoxon, p b 0.001, Fig. 2E).
3.6. CGRP- and tyrosine hydroxylase-immunoreactive nerve ﬁbers in the
dura mater and medullary pia mater
In the parietal dura mater and medullary pia mater whole mount
preparations CGRP-immunoreactive nerve ﬁbers were seen running in
small nerve bundles or as single axons, which formed branches and
loose nerve plexuses around arterial blood vessels. In the dura materer with potassium chloride causes CGRP release into the cerebrospinal
016/j.npep.2017.02.080
Fig. 2. CGRP concentrations measured in the cerebrospinal ﬂuid (CSF) of the cisterna
magna (A–C), the plasma of the jugular vein (D) and the SIF in the hemisected rat head
lined with dura mater (E). A: Decrease in CGRP concentrations in the course of the
surgery, immediately after opening of the cisterna magna (post prep) and 15 min later,
immediately after the craniotomy (post cran) and at regular intervals of 15 min; *
different to all other measurements, + different only to the 60 min value (repeated
measures ANOVA and LSD test). B: CGRP concentrations in the CSF before (Baseline)
and after topical application of KCl (60 mM) onto the dura mater. C: Same as in B but
after lidocaine injection into the trigeminal ganglion. D: CGRP levels in jugular plasma
before and after stimulation of the dura mater with KCl (60 mM) compared to baseline.
E: CGRP concentrations at baseline (5 and 10 min) and after KCl (60 mM)
administration. * Signiﬁcant difference from baseline in B–E.
Fig. 3. Immunohistochemical staining of nerve ﬁbers in whole mounts of the rat parietal
dura mater (A) and the dorsal medullary pia mater (B). A: Nerve ﬁbers immunoreactive
to CGRP (red) and to tyrosine hydroxylase (green) in the dura accompany arterial blood
vessels (MMA, branch of the middle meningeal artery). MV, meningeal venous vessel. B:
In the medullary pia mater an artery (PA) extending from the pial layer (P) is
innervated by a branched CGRP-immunoreactive ﬁber (green). B is composed of a stack
of 9 images at a distance of 3 μm.
5M. Dux et al. / Neuropeptides xxx (2017) xxx–xxxtyrosine hydroxylase-immunoreactive nerve ﬁber bundles were seen in
close proximity to both CGRP-immunoreactive afferents andmeningeal
arteries (Fig. 3).
4. Discussion
Neurovascular changes induced by the release of vasoactive neuro-
peptides from trigeminal afferents into meningeal tissues can be used
to indirectly assess changes in trigeminal afferent activity. VasodilatoryPlease cite this article as: Dux, M., et al., Stimulation of rat cranial duramat
ﬂuid and increases medul..., Neuropeptides (2017), http://dx.doi.org/10.1effects can bemeasured by videomicroscopy as calibre changes ofmen-
ingeal arteries (Akerman et al., 2002; Petersen et al., 2004; Williamson
et al., 1997) and by blood ﬂow recordings using laser Doppler
ﬂowmetry (Carmody et al., 1996; Dux et al., 2003, 2007; Kurosawa et
al., 1995). Vasoactive neuropeptides like substance P and CGRP released
from trigeminal afferents have been quantiﬁed using radioimmunoas-
say (Durham et al., 2006; Flores et al., 2001; Garry and Hargreaves,
1992; Knight et al., 1999) and ELISA methods (Eberhardt et al., 2008;
Ebersberger et al., 1999; Gupta et al., 2010; Messlinger et al., 1995;
Sauer et al., 2001; Strecker et al., 2006). Here we report a new model
combining both bloodﬂow recordings in the duramater and themedul-
la oblongata with the measurement of CGRP which is released from
these tissues and drained into the jugular vein and the CSF. KCl at
60 mMdepolarizingmeningeal nerve ﬁbers was applied to the exposed
cranial dura mater to induce CGRP release into the cranial circulation
and the cerebrospinal ﬂuid accompanied by increased medullary
blood ﬂow, which was abolished after local anaesthesia of the trigemi-
nal ganglion. In the hemisected rat preparation a similar amount ofer with potassium chloride causes CGRP release into the cerebrospinal
016/j.npep.2017.02.080
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such as transient receptor potential vanilloid 1 (TRPV1) through ago-
nists like capsaicin at concentrations of 0.1–1 μM (Gupta et al., 2010).
However, repetitive stimulation with capsaicin causes tachyphylaxis,
and at concentrations of ≥1 μM capsaicin decreases meningeal blood
ﬂow, most likely by a direct action on meningeal arteries (Dux et al.,
2003). Thus KCl appeared advantageous for these types of experiments.4.1. CGRP release into blood and CSF from different sources
The concentration of CGRP in the jugular blood was in the range of
reported plasma concentrations found in the rat (Hoffmann et al.,
2012) or pig (Arulmani et al., 2004b). In the cat and in humans jugular
CGRP levels have been reported to be higher, whichmay be due to spe-
cies differences (Goadsby and Edvinsson, 1993; Goadsby et al., 1988;
Knight et al., 1999, 2001; Zagami et al., 1990).
The CGRP levels measured in the CSF collected from the cisterna
magna are also in agreement with a study of Hoffmann et al. (2012)
(Hoffmann et al., 2012). The basal levels are nearly one order of magni-
tude higher than in jugular plasma, raising questions about the sites
from which CGRP is released and by which routes CGRP is drained.
Since a blood-brain barrier is lacking in the dura mater, most of the
CGRP released from meningeal afferent ﬁbers is probably ﬁltrated into
capillaries and postcapillary venules (Fig. 4). The venous blood is
drained via dural veins into the sagittal and transverse sinuses and
eventually in the jugular vein. It is less likely that the CGRP released
from dural afferents appears primarily in the CSF, because the cranial
dura mater is isolated from the subarachnoidal space by the subdural
neurothelium, the cells of which are connected by tight junctions
(Rascol and Izard, 1976). Other investigations showed that a diffusion
barrier between dura mater and the subarachnoidal space is mainly
composed of a pial (outer arachnoid) layer beneath the dura (Feurer
and Weller, 1991).
Pial arteries running through the subarachnoidal space are also in-
nervated by CGRP-immunoreactive nerve ﬁbers (Edvinsson et al.,
1987; Fricke et al., 2001), and the same applies for blood vessels in the
pia mater covering the medulla, as demonstrated by immunohisto-
chemistry (see Figs. 3 and 4). CGRP released from these ﬁbers is proba-
bly directly drained into the CSF; it is unlikely that much of this CGRP is
ﬁltrated into the cerebral blood vessels, where it must cross the blood-
brain barrier, which is functionally a blood-liquor barrier in this case.
Whether and at which amount CGRP is able to penetrate this barrier
in either direction is unknown. Small butmeasurable amounts of neuro-
peptides of a size comparable with that of CGRP have been reported to
be taken up by the brain through the blood-brain barrier (reviewed in
(Ermisch et al., 1985)); for 3H-labeled substance P this rate is about
0.5%. Inversely, some CGRP may slowly move into the venous systemFig. 4. Release from trigeminal afferents and proposed drainage of CGRP inmeningeal tissues. In
preferably drained into dural venous vessels (DV) eventually appearing in the blood of the jugu
preventing CGRP to move into the subarachnoidal space. In contrast, CGRP released from tr
oblongata is most likely diffusing into the CSF of the subarachnoidal space or the cisterna m
(BBB), which is in case of pial vessels a blood-liquor barrier. Most of the CGRP appearing in
nucleus (STN), where CGRP cannot cross the BBB to diffuse into the blood vessels. This is evid
blood ﬂow after anaesthesia of the trigeminal ganglion.
Please cite this article as: Dux, M., et al., Stimulation of rat cranial duramat
ﬂuid and increases medul..., Neuropeptides (2017), http://dx.doi.org/10.1together with the CSF absorbed through the arachnoidal (Pacchioni)
granulations.
Regarding the relatively high CGRP concentrations found in the CSF
compared to blood plasma, a signiﬁcant proportion of CGRP may be re-
leased from the central terminals of trigeminal afferents in superﬁcial
layers of the spinal trigeminal nucleus (Lennerz et al., 2008), probably
diffusing to the dorsal surface of themedulla oblongata and into the sur-
rounding ventricular space (Fig. 4). This assumption is supported by the
ﬁnding that anaesthesia of the trigeminal ganglion abolished the in-
crease in CGRP levels in the CSF caused by meningeal KCl application.
Using the microprobe techniques we have earlier shown that noxious
stimulation of the duramater by acidic solution caused considerable ac-
cumulation of substance P in superﬁcial layers of the spinal trigeminal
nucleus (Schaible et al., 1997). In a newly designed preparation we
found high amounts of CGRP released from medulla oblongata slices
of mice after stimulation with capsaicin or KCl (Kageneck et al., 2014).
Different to the blood plasma, CGRP can probably accumulate in the
CSF because of the lack of peptidases (especially the neutral endopepti-
dase), which rapidly break down CGRP in the blood plasma.
4.2. Vascular effects of released CGRP
Regardless of looking at the venous plasma or the CSF, it is question-
able if the low CGRP concentrations found in either compartment can
cause signiﬁcant vasodilatation. Isolated cerebral arteries of different
species (cat, rabbit, rat) preconstricted with PGF2α showed half-maxi-
mal relaxation (EC50) with CGRP in the range of 5–10 nM (19–
38 ng/ml) (Edvinsson et al., 1985, 1987; McCulloch et al., 1986) and
the EC50 for CGRP to relax rat intracerebral arterioles was 3.9 nM
(15 ng/ml) (Edwards et al., 1991) but in jugular plasma the CGRP con-
centration was not above 5.3 pM (20 pg/ml). Even CGRP at 25 pM
(95 pg/ml) concentration as found in the CSF during the steady state
of sampling in our experiments may not cause relevant vasorelaxation.
The CGRP concentrations at the blood vessels innervated by these ter-
minals can be considered to be higher by several orders, which easily
explains their potent vasodilatory capacity (see Figs. 3 and 4). Taken to-
gether, it is unlikely that the CGRP released into the CSF can cause a de-
tectable increase in medullary blood ﬂow, rather it is the direct
vasodilatory effect of activated primary afferent terminals within the
spinal trigeminal nucleus that drives an increased blood supply, possi-
bly supplemented by the direct innervations of the pialmedullary arter-
ies as evident from immunohistochemistry.
4.3. Neuronal and vascular effects of KCl
Topical application of depolarizing potassium concentrations caused
a decrease in meningeal blood ﬂow unless the dura mater was
pretreated with phentolamine blocking alpha-adrenoceptors. Thisthe duramater CGRP released fromperivascular afferents innervating dural arteries (DA) is
lar vein. The outer arachnoid layer, which is regarded as a barrier for peptides, is probably
igeminal afferents innervating pial arteries (PA) of the cerebral cortex and the medulla
agna, respectively, since cortical blood vessels are equipped with a blood-brain barrier
the CSF may be released from the central trigeminal terminals in the spinal trigeminal
enced by the lacking rise of CGRP levels in the CSF and the lacking elevation in medullary
er with potassium chloride causes CGRP release into the cerebrospinal
016/j.npep.2017.02.080
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ﬁbers, which richly supply dural arteries (Edvinsson and Uddman,
1981; Keller et al., 1989) and counteract the CGRP mediated
vasodilatory effect upon the release of vasoconstrictory mediators like
norepinephrine. Nevertheless, after blocking alpha-adrenoceptors, KCl
still failed to increase the meningeal blood ﬂow signiﬁcantly, which
may indicate further mechanisms counteracting the vasodilatory action
of CGRP. In contrast, KCl application onto the dura caused a small but
consistent increase in medullary blood ﬂow. The vasodilatory effect of
CGRP in meningeal and cerebral arteries as in several other arterial ves-
sels has been shown to depend preferably on the activation of ATP-sen-
sitive K+ channels (KATP) and the subsequent hyperpolarisation of the
vascular smooth muscle cells through K+ outﬂow (Gozalov et al.,
2005; Ko et al., 2008; Quayle et al., 1997). This potent mechanism
seems to be compensated by direct vascular smoothmuscle depolariza-
tion induced by K+ resulting in a net effect of near zero arterial vasodi-
latation. Since at an extracellular concentration of 60 mM K+ the
reversal potential of KATP channels is close to−20mV, voltage-sensitive
Ca2+ channels are open and activate contraction of smooth vascular
muscle cells (Nelson and Quayle, 1995). Phentolamine can antagonize
the effect of released noradrenalin but not the direct depolarizing effect
of KCl.
KCl application to the cortical surface is an establishedmethod to in-
duce cortical spreading depression, which is characterized bymetabolic
disturbance in superﬁcial cortical areas accompanied by a transient in-
crease in ﬂow followed by long-lasting suppression of cortical functions
(Ueda et al., 1997). In our experiments there was not any evidence for
CSD-related changes in meningeal or medullary blood ﬂow following
KCl application to the dura mater.
4.4. Effects of trigeminal ganglion anaesthesia
Injection of lidocaine into the ipsilateral trigeminal ganglion
abolished the increase inmedullary blood ﬂow evoked by local stimula-
tion of the dura mater with KCl. This treatment presumably blocked all
the activity conducted through the ganglion. Anaesthesia of the trigem-
inal ganglion has previously been shown to reduce the ongoing activity
of spinal trigeminal neurons with meningeal afferent input (Roch et al.,
2007) indicating that a certain amount of afferent input is required to
drive the activity of second order neurons. Thus it is likely that blood
ﬂow increases following dilatation of medullary blood vessels depend
primarily on CGRP release from the central afferent terminals in the spi-
nal trigeminal nucleus.
4.5. Clinical implications
The release of CGRP in the spinal trigeminal nucleus is of consider-
able relevance for the understanding of central nociceptivemechanisms
involved in trigeminal nociception as the basic principle of headache
and facial pain. Peripheral sensitization of trigeminal afferents leading
to enhanced release of CGRP in the trigeminal nucleus is considered as
the major peripheral pathophysiological mechanism involved in the
generation of primary headaches. Moreover, CGRP is a modulator of no-
ciceptive processing on the level of the dorsal horn and the spinal tri-
geminal nucleus (Storer et al., 2004; Sun et al., 2004; Yu et al., 2002).
Our group and others have provided evidence that this central CGRP-
driven neurotransmission is an important site for CGRP receptor inhib-
itors reducing pain in migraine attacks (Fischer et al., 2005; Sixt et al.,
2009; Storer et al., 2004). CGRP is released upon direct stimulation of
the human and cat trigeminal ganglion (Goadsby and Edvinsson,
1993; Goadsby et al., 1988) and during attacks of migraine and cluster
headache (Goadsby and Edvinsson, 1994; Goadsby et al., 1990), i.e. dur-
ing events likely to be associated with strong activation of meningeal
nociceptors. This has been evidenced based on measurements of CGRP
plasma levels either in the venous outﬂow from the head (Goadsby et
al., 1990) or in peripheral veins (Goadsby et al., 1988). We can nowPlease cite this article as: Dux, M., et al., Stimulation of rat cranial duramat
ﬂuid and increases medul..., Neuropeptides (2017), http://dx.doi.org/10.1speculate from our experiments that a considerable part of the CGRP re-
leased from activated trigeminal afferents during experimental condi-
tions or severe attacks of primary headaches is drained into the CSF
and does not appear in the venous system. Most of the CGRP in the
CSF may be released from central terminals of meningeal afferents in
the spinal trigeminal nuclear complex.
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